Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: Which is better?

Basit Öğe Kaydı
dc.authorscopusid57209661764
dc.authorscopusid57222525890
dc.authorscopusid57514476300
dc.authorscopusid56497709600
dc.authorscopusid57200544019
dc.authorscopusid57218372808
dc.authorscopusid8665552100
dc.contributor.authorAktepe, Oktay Halit
dc.contributor.authorArdic, Fadime Sinem
dc.contributor.authorYuce, Deniz
dc.contributor.authorGuven, Deniz Can
dc.contributor.authorGuner, Gurkan
dc.contributor.authorYildirim, Hasan Cagri
dc.contributor.authorKilickap, Saadettin
dc.date.accessioned2024-09-25T19:43:10Z
dc.date.available2024-09-25T19:43:10Z
dc.date.issued2021
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractPurpose: The objective of the present study was to compare the efficacy of axitinib and nivolumab in metastatic renal cell carcinoma (mRCC) previously treated with targeted therapy. Methods: A total of 79 patients were enrolled (39 patients in axitinib group, 40 patients in nivolumab group). Survival outcomes of patients, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier method and compared with the log-rank test. The associations between potential prognostic variables and OS were evaluated in univariate and multivariate Cox regression analyses. Results: The median PFS and OS of all cohort were 8.1 and 36.6 months, respectively. Higher PFS and OS were evaluated in axitinib group than nivolumab group (PFS: 9.4 months vs 6.3 m2onths, p=0.386; OS: 38.2 months vs 36.6 months, p=0.671, respectively). Patients treated with axitinib had numerically higher objective response rate (ORR) and disease control rate (DCR) than those treated with nivolumab (ORR: 43.6% vs 27.6%, p=0.157, DCR: 74.4% vs 62.5%, p=0.157, respectively). Multivariate analysis revealed that the independent predictors of OS were higher tumor grade (hazard ratio [HR]: 6.178, p=0.004), worse response to axitinib and nivolumab (HR:4.902, p=0.011), the presence of lung metastasis (HR:15.637, p=0.002) and the presence of liver metastasis (HR:12.010, p=0.001). Conclusion: Comparable survival outcomes were detected in the axitinib and nivolumab groups. However, head to head comparisons are needed to highlight the relative efficacy of these therapies in mRCC.. © 2021 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage2073en_US
dc.identifier.issn1107-0625
dc.identifier.issue5en_US
dc.identifier.pmid34761618en_US
dc.identifier.scopus2-s2.0-85118731000en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2067en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/12482
dc.identifier.volume26en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectAxitiniben_US
dc.subjectMetastatic renal cell carcinomaen_US
dc.subjectNivolumaben_US
dc.subjectPrognosisen_US
dc.subjectTargeted therapyen_US
dc.titleEfficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: Which is better?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu